{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T01:50:24Z","timestamp":1769737824158,"version":"3.49.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,5]]},"DOI":"10.7759\/cureus.55549","type":"journal-article","created":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T11:16:28Z","timestamp":1709637388000},"source":"Crossref","is-referenced-by-count":1,"title":["Exocrine Pancreatic Insufficiency During the Use of Semaglutide: A Case Report"],"prefix":"10.7759","author":[{"given":"Clivaldo","family":"Agra de Melo Junior","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norberto Eloi","family":"Gomes J\u00fanior","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco Aur\u00e9lio","family":"da Silva Ribeiro-Sousa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selma Freire de Carvalho","family":"Cunha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1159\/000497124","article-title":"The ABCD of obesity: an EASO position statement on a diagnostic term with clinical and scientific implications","volume":"12","author":"Fr\u00fchbeck G","year":"2019","unstructured":"Fr\u00fchbeck G, Busetto L, Dicker D, et al.. The ABCD of obesity: an EASO position statement on a diagnostic term with clinical and scientific implications. Obes Facts. 2019, 12:131-6. 10.1159\/000497124","journal-title":"Obes Facts"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1177\/2042018821997320","article-title":"GLP-1 receptor agonists: an updated review of head-to-head clinical studies","volume":"12","author":"Trujillo JM","year":"2021","unstructured":"Trujillo JM, Nuffer W, Smith BA. GLP-1 receptor agonists: an updated review of head-to-head clinical studies. Ther Adv Endocrinol Metab. 2021, 12:2042018821997320. 10.1177\/2042018821997320","journal-title":"Ther Adv Endocrinol Metab"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/jim-2021-001952","article-title":"Wegovy (semaglutide): a new weight loss drug for chronic weight management","volume":"70","author":"Singh G","year":"2022","unstructured":"Singh G, Krauthamer M, Bjalme-Evans M. Wegovy (semaglutide): a new weight loss drug for chronic weight management. J Investig Med. 2022, 70:5-13. 10.1136\/jim-2021-001952","journal-title":"J Investig Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.645563","article-title":"Safety of semaglutide","volume":"12","author":"Smits MM","year":"2021","unstructured":"Smits MM, Van Raalte DH. Safety of semaglutide. Front Endocrinol (Lausanne). 2021, 12:645563. 10.3389\/fendo.2021.645563","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1043789","article-title":"Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database","volume":"13","author":"Liu L","year":"2022","unstructured":"Liu L, Chen J, Wang L, Chen C, Chen L. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database. Front Endocrinol (Lausanne). 2022, 13:1043789. 10.3389\/fendo.2022.1043789","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.23736\/S2724-6507.20.03219-8","article-title":"Pancreatitis and pancreatic cancer in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials","volume":"48","author":"Nreu B","year":"2023","unstructured":"Nreu B, Dicembrini I, Tinti F, Mannucci E, Monami M. Pancreatitis and pancreatic cancer in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials. Minerva Endocrinol (Torino). 2023, 48:206-13. 10.23736\/S2724-6507.20.03219-8","journal-title":"Minerva Endocrinol (Torino)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff AM","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023, 389:2221-32. 10.1056\/NEJMoa2307563","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.15605\/jafes.037.02.14","article-title":"Efficacy and safety of semaglutide for weight loss in obesity without diabetes: a systematic review and meta-analysis","volume":"37","author":"Tan HC","year":"2022","unstructured":"Tan HC, Dampil OA, Marquez MM. Efficacy and safety of semaglutide for weight loss in obesity without diabetes: a systematic review and meta-analysis. J ASEAN Fed Endocr Soc. 2022, 37:65-72. 10.15605\/jafes.037.02.14","journal-title":"J ASEAN Fed Endocr Soc"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding JP","year":"2021","unstructured":"Wilding JP, Batterham RL, Calanna S, et al.. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021, 384:989-1002. 10.1056\/NEJMoa2032183","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.996179","article-title":"Gastrointestinal adverse events associated with semaglutide: a pharmacovigilance study based on FDA adverse event reporting system","volume":"10","author":"Shu Y","year":"2022","unstructured":"Shu Y, He X, Wu P, Liu Y, Ding Y, Zhang Q. Gastrointestinal adverse events associated with semaglutide: a pharmacovigilance study based on FDA adverse event reporting system. Front Public Health. 2022, 10:996179. 10.3389\/fpubh.2022.996179","journal-title":"Front Public Health"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2022.102427","article-title":"Adverse drug reactions of GLP-1 agonists: a systematic review of case reports","volume":"16","author":"Shetty R","year":"2022","unstructured":"Shetty R, Basheer FT, Poojari PG, Thunga G, Chandran VP, Acharya LD. Adverse drug reactions of GLP-1 agonists: a systematic review of case reports. Diabetes Metab Syndr. 2022, 16:102427. 10.1016\/j.dsx.2022.102427","journal-title":"Diabetes Metab Syndr"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.19574","article-title":"Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss","volume":"330","author":"Sodhi M","year":"2023","unstructured":"Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. JAMA. 2023, 330:1795-7. 10.1001\/jama.2023.19574","journal-title":"JAMA"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.43773","article-title":"Acute pancreatitis in a patient taking semaglutide","volume":"15","author":"Patel F","year":"2023","unstructured":"Patel F, Gan A, Chang K, Vega KJ. Acute pancreatitis in a patient taking semaglutide. Cureus. 2023, 15:e43773. 10.7759\/cureus.43773","journal-title":"Cureus"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.39011","article-title":"Severe, complicated pancreatitis with an unclear etiology","volume":"15","author":"Nohomovich B","year":"2023","unstructured":"Nohomovich B, Shah A, Hughes N. Severe, complicated pancreatitis with an unclear etiology. Cureus. 2023, 15:e39011. 10.7759\/cureus.39011","journal-title":"Cureus"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al.. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016, 375:1834-44. 10.1056\/NEJMoa1607141","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-2747","article-title":"Amylase, lipase, and acute pancreatitis in people with type 2 diabetes treated with liraglutide: results from the LEADER randomized trial","volume":"40","author":"Steinberg WM","year":"2017","unstructured":"Steinberg WM, Buse JB, Ghorbani ML, \u00d8rsted DD, Nauck MA. Amylase, lipase, and acute pancreatitis in people with type 2 diabetes treated with liraglutide: results from the LEADER randomized trial. Diabetes Care. 2017, 40:966-72. 10.2337\/dc16-2747","journal-title":"Diabetes Care"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-2684","article-title":"Impact of liraglutide on amylase, lipase, and acute pancreatitis in participants with overweight\/Obesity and normoglycemia, prediabetes, or type 2 diabetes: secondary analyses of pooled data from the SCALE clinical development program","volume":"40","author":"Steinberg WM","year":"2017","unstructured":"Steinberg WM, Rosenstock J, Wadden TA, Donsmark M, Jensen CB, DeVries JH. Impact of liraglutide on amylase, lipase, and acute pancreatitis in participants with overweight\/Obesity and normoglycemia, prediabetes, or type 2 diabetes: secondary analyses of pooled data from the SCALE clinical development program. Diabetes Care. 2017, 40:839-48. 10.2337\/dc16-2684","journal-title":"Diabetes Care"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.pan.2022.03.013","article-title":"Diagnosis and treatment of exocrine pancreatic insufficiency in chronic pancreatitis: an international expert survey and case vignette study","volume":"22","author":"de Rijk FE","year":"2022","unstructured":"de Rijk FE, van Veldhuisen CL, Besselink MG, et al.. Diagnosis and treatment of exocrine pancreatic insufficiency in chronic pancreatitis: an international expert survey and case vignette study. Pancreatology. 2022, 22:457-65. 10.1016\/j.pan.2022.03.013","journal-title":"Pancreatology"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31318-0","article-title":"Chronic pancreatitis","volume":"396","author":"Beyer G","year":"2020","unstructured":"Beyer G, Habtezion A, Werner J, Lerch MM, Mayerle J. Chronic pancreatitis. Lancet. 2020, 396:499-512. 10.1016\/S0140-6736(20)31318-0","journal-title":"Lancet"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/227415-exocrine-pancreatic-insufficiency-during-the-use-of-semaglutide-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,5]],"date-time":"2024-03-05T11:16:31Z","timestamp":1709637391000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/227415-exocrine-pancreatic-insufficiency-during-the-use-of-semaglutide-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,5]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.55549","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3,5]]}}}